Clinics in Dermatology
Volume 30, Issue 1 , Pages 3-16 , January 2012

Bullous pemphigoid: From the clinic to the bench

  • Giovanni Di Zenzo, PhD

      Affiliations

    • Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, via Monti di Creta, 104, 00167 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 664 64734; fax: +39 06 664 64705.
    • ,
  • Rocco della Torre, BMBS

      Affiliations

    • Department of Dermatology, University Hospital-Inselspital, Freiburgstrasse, 3010 Berne, Switzerland
    • ,
  • Giovanna Zambruno, MD

      Affiliations

    • Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, via Monti di Creta, 104, 00167 Rome, Italy
    • ,
  • Luca Borradori, MD

      Affiliations

    • Department of Dermatology, University Hospital-Inselspital, Freiburgstrasse, 3010 Berne, Switzerland

References 

  1. Lipsker D, Borradori L. ‘Bullous’ pemphigoid: what are you? Urgent need of definitions and diagnostic criteria. Dermatology. 2010;221:131–134
  2. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group. Arch Dermatol. 1995;131:48–52
  3. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population based study on incidence. J Am Acad Dermatol. 1999;41:266–268
  4. Marazza G, Pham HC, Schärer L, et al. Autoimmune bullous disease Swiss study group. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161:861–868
  5. Bertram F, Bröcker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434–440
  6. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180
  7. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al. Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics. J Am Acad Dermatol. 2008;58:41–48
  8. Liu HN, Su WP, Rogers RS. Clinical variants of pemphigoid. Int J Dermatol. 1986;25:17–27
  9. Korman N. Bullous pemphigoid. J Am Acad Dermatol. 1987;16:907–924
  10. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol. 2007;23:257–288
  11. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008;128:415–426
  12. Castanet J, Lacour JP, Ortonne JP. Atypical clinical forms of bullous pemphigoid. Ann Dermatol Venereol. 1990;117:73–82
  13. Salomon RJ, Briggaman RA, Wernikoff SY, et al. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol. 1987;123:389–392
  14. Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol. 2005;44:942–945
  15. Ernst TM, Marsch WC. Develop of localized pemphigoid following radiation treatment. Dermatologica. 1982;164:73–81
  16. Borradori L, Prost C, Wolkenstein P, et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol. 1992;27:863–867
  17. Callens A, Vaillant L, Machet MC, et al. Localized atypical pemphigoid on lymphoedema following radiotherapy. Acta Derm Venereol. 1993;73:461–464
  18. Person JR. Hydrostatic bullae and pretibial pemphigoid. Int J Dermatol. 1983;22:237–238
  19. Schmidt E, Benoit S, Brocker EB. Bullous pemphigoid with localized umbilical involvement. Acta Derm Venereol. 2009;89:419–420
  20. Nunzi E, Rongioletti F, Parodi A, et al. Dyshidrosiform pemphigoid. J Am Acad Dermatol. 1988;19:568–569
  21. Descamps V, Flageul B, Vignon-Pennamen D, et al. Dyshidrosiform pemphigoid: report of three cases. J Am Acad Dermatol. 1992;26:651–652
  22. Farrell AM, Kirtschig G, Dalziel KL, et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol. 1999;140:308–312
  23. Bean SF, Michel B, Furey N, et al. Vesicular pemphigoid. Arch Dermatol. 1976;112:1402–1404
  24. Komine M, Nashiro K, Asahina A, et al. Vesicular pemphigoid. Int J Dermatol. 1992;31:868–870
  25. Ohnishi Y, Tajima S, Ishibashi A, et al. A vesicular bullous pemphigoid with an autoantibody against plectin. Br J Dermatol. 2000;142:813–815
  26. Ueda Y, Nashiro K, Seki Y, et al. Pemphigoid vegetans. Br J Dermatol. 1989;120:449–453
  27. Poulain JF, Carmi E, Thelu F, et al. Pigmented pemphigoid. Ann Dermatol Venereol. 1999;126:616–618
  28. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol. 1995;133:967–971
  29. Cliff S, Holden CA. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol. 1997;136:398–401
  30. Gengoux P, Lachapelle JM. Pemphigoid presenting as atypical excoriated prurigo: regarding 11 cases. Dermatology. 1997;194:392–394
  31. Alonso-Llamazares J, Dietrich SM, Gibson LE. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol. 1998;39:827–830
  32. Cordel N, Courville P, Martel P, et al. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant. Br J Dermatol. 2002;146:537–539
  33. Geiss Steiner J, Trueb RM, Kerl K, et al. Ecthyma-gangrenosum-like bullous pemphigoid. Dermatology. 2010;221:142–148
  34. Stingl G, Hollubar K. Coexistence of lichen planus and bullous pemphigoid. An immunopathological study. Br J Dermatol. 1975;93:313–320
  35. Sobel S, Miller R, Shatin H. Lichen planus pemphigoides, immunofluorescence findings. Arch Dermatol. 1976;112:1280–1283
  36. Trueb RM, Didierjean L, Fellas A, et al. Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol. 1999;40:338–344
  37. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996;132:272–276
  38. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk Factors for bullous pemphigoid in the elderly. A prospective case-control study. J Invest Dermatol. 2011;131:637–643
  39. Taylor G, Venning V, Wojnarowska F, et al. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol. 1993;29:181–184
  40. Kirtschig G, Chow ET, Venning VA, et al. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol. 1996;135:738–745
  41. Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?. Int J Dermatol. 2006;45:1353–1357
  42. Shipman AR, Cooper S, Wojnarowska F. Autoreactivity to bullous pemphigoid 180: is this the link between subepidermal blistering diseases and oral lichen planus?. Clin Exp Dermatol. 2011;36:267–269
  43. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol. 1990;126:66–68
  44. Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136–141
  45. Bourdon-Lanoy E, Roujeau JC, Joly P, et al. Bullous pemphigoid in young patients: a retrospective study of 74 cases. Ann Dermatol Venereol. 2005;132:115–122
  46. Taghipour K, Chi CC, Vincent A, et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010;146:1251–1254
  47. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131:631–636
  48. Jedlickova H, Hlubinka M, Pavlik T, et al. Bullous pemphigoid and internal diseases—A case-control study. Eur J Dermatol. 2010;20:96–101
  49. Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler. 2008;14:823–829
  50. Langer-Gould A, Albers KB, Van Den Eeden SK, et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010;16:855–861
  51. Leung CL, Zheng M, Prater SM, et al. The BPAG1 locus: Alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J Cell Biol. 2001;154:691–697
  52. Seppanen A, Suuronen T, Hofmann SC, et al. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50–56
  53. Chen J, Li L, Zeng Y, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2010;
  54. Guo L, Degenstein L, Dowling J, et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell. 1995;81:233–243
  55. Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol. 1998;134:1075–1080
  56. Joly P, Courville P, Lok C, et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology. 2004;208:16–20
  57. Magro CM, Dyrsen ME. The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease. J Am Acad Dermatol. 2008;59:822–833
  58. Pfaltz K, Mertz K, Rose C, et al. C3d immunohistochemistry on formalin-fixed tissue is a valuable tool in the diagnosis of bullous pemphigoid of the skin. J Cutan Pathol. 2010;37:654–658
  59. Gammon WR, Kowalewski C, Chorzelski TP, et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990;22:664–670
  60. Vodegel RM, Jonkman MF, Pas HH, et al. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004;151:112–118
  61. De Jong MC, Bruins S, Heeres K, et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996;132:151–157
  62. Gammon WR, Briggaman RA, Inman AO, et al. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol. 1984;82:139–144
  63. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109:679–683
  64. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol. 1998;139:365–370
  65. Husz S, Kiss M, Molnar K, et al. Development of a system for detection of circulating antibodies against hemdesmosomal proteins in patients with bullous pemphigoid. Arch Dermatol Res. 2000;292:217–224
  66. Hata Y, Fujii Y, Tsunoda K, et al. Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression. J Dermatol Sci. 2000;23:183–190
  67. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002;30:224–232
  68. Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002;119:1065–1073
  69. Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol. 2004;151:126–131
  70. Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol. 2004;151:1004–1010
  71. Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180 specific autoantibodies in bullous pemphigoid. J Invest Dermatol. 2004;122:1413–1422
  72. Kromminga A, Sitaru C, Hagel C, et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol. 2004;111:146–152
  73. Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37:145–149
  74. Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci. 2006;41:21–30
  75. Sitaru C, Dähnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol. 2007;16:770–777
  76. Feng S, Lin L, Jin P, et al. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China. Int J Dermatol. 2008;47:24–28
  77. Tampoia M, Lattanzi V, Zucano A, et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci. 2009;1173:15–20
  78. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol. 2011;147:286–291
  79. Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol. 2011;147:293–298
  80. Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol. 2009;145:537–542
  81. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465–469
  82. Colbert RL, Allen DM, Eastwood D, et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122:1091–1095
  83. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138:903–908
  84. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005;141:691–698
  85. Bernard P, Enginger V, Venot J, et al. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol. 1995;122:751–757
  86. Garcia-Doval I, Conde Taboada A, Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol. 2005;124:666–667
  87. Korman NJ. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin. 2000;18:127–137
  88. Laffitte E, Borradori L. Fiche thérapeutique: prise en charge de la pemphigoïde bulleuse. Ann Dermatol Venerol. 2001;128:677–680
  89. Joly P, Roujeau JC, Benichou J, et al. Bullous Diseases French Study Group: a comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321–327
  90. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129:1681–1687
  91. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111:925–928
  92. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120:518–521
  93. Burton JL, Harman RM, Peachey RD, et al. A controlled trial of azathioprine in the treatment of pemphigoid [proceedings]. Br J Dermatol. 1978;99:14
  94. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129:49–53
  95. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536–1542
  96. Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120:83–92
  97. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;6:753–758
  98. Reguiaï Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009;136:431–434
  99. Haase C, Büdinger L, Borradori L, et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol. 1998;110:282–286
  100. Schmidt E, Obe K, Brocker EB, et al. Serum levels of autoantibdies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–178
  101. Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol. 1999;112:411–418
  102. Giudice GJ, Squiquera HL, Elias PM, et al. Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest. 1991;87:734–738
  103. Hopkinson SB, Riddelle KS, Jones JCR. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J Invest Dermatol. 1992;99:264–270
  104. Jonkman MF, de Jong MC, Heeres K, et al. 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J Clin Invest. 1995;95:1345–1352
  105. McGrath JA, Gatalica B, Christiano AM, et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nature Genet. 1995;11:83–86
  106. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest. 1988;82:1864–1870
  107. Sawamura D, Li K, Chu ML, et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem. 1991;266:17784–17790
  108. Green KJ, Virata MLA, Elgart GW, et al. Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: members of a new gene family involved in organization of intermediate filaments. Int J Biol Macromol. 1992;14:145–153
  109. Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol. 2010;130:1551–1557
  110. Diaz LA, Ratrie H, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. J Clin Invest. 1990;86:1088–1094
  111. Giudice GJ, Emery DJ, Zelickson BD, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151:5742–5750
  112. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 1994;102:878–881
  113. Perriard J, Jaunin F, Favre B, et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domain of the BP antigen 180. J Invest Dermatol. 1999;112:141–147
  114. Nie Z, Hashimoto T. IgA antibodies of cicatricial pemphigoid sera specifically react with terminus of BP180. J Invest Dermatol. 1999;112:254–255
  115. Egan CA, Taylor TB, Meyer LJ, et al. Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. J Invest Dermatol. 1999;112:148–152
  116. Schumann H, Baetge J, Tasanen K, et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol. 2000;156:685–695
  117. Egan CA, Reddy D, Nie Z, et al. IgG anti-LABD97 antibodies in bullous pemphigoid patients' sera react with the mid-portion of the BPAg2 ectodomain. J Invest Dermatol. 2001;116:348–350
  118. Di Zenzo G, Grosso F, Terracina M, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol. 2004;122:103–110
  119. Thoma-Uszynski S, Uter W, Schwietzke S, et al. Auto-reactive T and B cells from bullous pemphigoid (BP) patients recognize similar antigenic regions of BP180 and BP230. J Immunol. 2006;176:2015–2023
  120. Skaria M, Jaunin F, Hunziker T, et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol. 2000;114:998–1004
  121. Hamada T, Nagata Y, Tomita M, et al. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol. 2001;10:256–263
  122. Tanaka M, Hashimoto T, Amagai M, et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol. 1991;97:725–728
  123. Miller JE, Rico JM, Hall RP. IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol. 1993;101:779–782
  124. Ide A, Hashimoto T, Amagai M, et al. Detection of autoantibodies against the bullous pemphigoid and pemphigus antigens by an enzyme-linked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol. 1995;5:112–116
  125. Gaucherand M, Nicolas JF, Paranhos Baccala G, et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein. Evidence using a 55 kDa recombinant protein. Br J Dermatol. 1995;132:190–196
  126. Ghohestani RF, Cozzani E, Delaporte E, et al. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol. 1998;18:202–209
  127. Christophoridis S, Budinger L, Borradori L, et al. IgG, IgA and IgE antibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol. 2000;143:349–355
  128. Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol. 2005;125:467–472
  129. Messingham KA, Noe MH, Chapman MA, et al. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods. 2009;346:18–25
  130. Dresow SK, Sitaru C, Recke A, et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160:429–432
  131. Büdinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998;102:2082–2089
  132. Lin MS, Gharia MA, Swartz SJ, et al. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol. 1999;162:4991–4997
  133. Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci. 1996;93:8569–8571
  134. Romagnani S. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Appl Immunol. 1992;98:279–285
  135. Bernard P, Aucouturier P, Denis F, et al. Immunoblot analysis of IgG subclass of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopath. 1990;54:484–494
  136. D'Auria L, Cordiali Fei P, Ameglio F. Cytokines and bullous pemphigoid. Eur Cytokine Netw. 1999;10:123–134
  137. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480–2488
  138. Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest. 1995;95:1539–1544
  139. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. 1997;100:1256–1263
  140. Liu Z, Shipley JM, Vu TH, et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med. 1998;188:475–482
  141. Liu Z, Shapiro SD, Zhou X, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105:113–123
  142. Liu Z, Zhou X, Shapiro SD, et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000;102:647–655
  143. Liu Z, Li N, Diaz LA, et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest. 2005;115:879–887
  144. Liu Z, Sui W, Zhao M, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun. 2008;31:331–338
  145. Yamamoto K, Inoue N, Masuda R, et al. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol. 2002;118:485–492
  146. Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med. 2007;13:378–383
  147. Nishie W, Sawamura D, Natsuga K, et al. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J Immunol. 2009;183:4088–4093
  148. Gammon WR, Inman AO, Wheeler CE. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods. J Invest Dermatol. 1984;83:57–61
  149. Stahle-Bäckdahl M, Inoue M, Giudice GJ, et al. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180 kD in bullous pemphigoid autoantigen. J Clin Invest. 1994;93:2022–2030
  150. Verraes S, Hornebeck W, Polette M, et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol. 2001;117:1091–1096
  151. Shimanovich I, Mihai S, Oostingh GJ, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol. 2004;204:519–527
  152. Nelson KC, Zhao M, Schroeder PR, et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest. 2006;116:2892–2900
  153. Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108:1151–1158
  154. Chen R, Fairley JA, Zhao ML, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophilinfiltration depends on mast cell activation. J Immunol. 2002;169:3987–3992
  155. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664–671
  156. Zhao M, Trimbeger ME, Li N, et al. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol. 2006;177:3398–3405
  157. Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120:784–788
  158. Fairley JA, Burnett CT, Fu CL, et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol. 2007;127:2605–2611
  159. Zone JJ, Taylor T, Hull C, et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol. 2007;127:1167–1174
  160. Hall RP, Murray JC, McCord MM, et al. Rabbits immunized with a peptide encoded for by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol. 1993;101:9–14
  161. Kiss M, Husz S, Janossy T, et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun. 2005;24:1–10
  162. Di Zenzo G, Calabresi V, Olasz EB, et al. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J Invest Dermatol. 2010;130:1040–1047
  163. Olasz EB, Roh J, Yee CL, et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol. 2007;127:2807–2817
  164. Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol. 2010;184:2166–2174

PII: S0738-081X(11)00081-2

doi: 10.1016/j.clindermatol.2011.03.005

Clinics in Dermatology
Volume 30, Issue 1 , Pages 3-16 , January 2012

Article Tools

* Image Usage & Resolution